Advanced Ovarian Cancer Clinical Trial
Official title:
Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer
Our study aims at assessment of response, survival and toxicity of frontline treatment with chemotherapy and Bevacizumab in patients having advanced epithelial ovarian cancer.
Ovarian cancer is the most lethal gynecologic malignancy and is the fifth most common cause
of cancer death in women .The majority of women with ovarian cancer are diagnosed with
advanced-stage disease; only 15% of all cases are diagnosed with local disease. Risk factors
for ovarian cancer include family history, nulliparity, lack of breast feeding, and
infertility .
The GOG-0218 trial demonstrated that the use of bevacizumab in the front-line and maintenance
setting improved progression free survival by 3.8 months when compared with conventional
every-3-weeks carboplatin and paclitaxel.
The ICON-7 trial also aimed to compare the progression free survival and Overall survival in
women who receive bevacizumab with carboplatin/paclitaxel and women receiving
carboplatin/paclitaxel alone The final results of ICON7 were announced in 2013. Overall, the
results showed no difference in overall survival between those in the group receiving
bevacizumab han those in the group receiving no bevacizumab. However, for high-risk patients,
who were most likely to have early disease progression, the results were positive and showed
an improvement in overall survival of 4.8 months in the group who received bevacizumab.
Not only has the best route been intensely debated but the optimal timing of therapy has been
and is currently being studied. Chemotherapy is usually given either only after primary
debulking surgery or as both neoadjuvant chemotherapy before and after interval debulking
surgery. recent trials have tried to determine which treatment timing is associated with
better outcomes .
The aim of the study will be assessment of response, survival and toxicity of frontline
treatment with chemotherapy and Bevacizumab in patients having advanced epithelial ovarian
cancer.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06055348 -
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT04135521 -
Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer
|
||
| Completed |
NCT01462149 -
Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer
|
Phase 2 | |
| Terminated |
NCT03292172 -
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT05794659 -
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT04360629 -
Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer
|
N/A | |
| Completed |
NCT00516724 -
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
|
Phase 1 | |
| Completed |
NCT03158935 -
The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
|
Phase 1 | |
| Completed |
NCT05775549 -
A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
|
||
| Active, not recruiting |
NCT03737643 -
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
|
Phase 3 | |
| Completed |
NCT01290471 -
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT04862325 -
SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS
|
N/A | |
| Completed |
NCT01989546 -
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04556539 -
Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT03161132 -
Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin
|
Phase 2 | |
| Active, not recruiting |
NCT04065009 -
The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT01844986 -
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
|
Phase 3 | |
| Not yet recruiting |
NCT05924776 -
Plasmodium Immunotherapy for Advanced Ovarian Cancer
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03878849 -
Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®
|
Phase 2 |